2-(7-amino-1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-N-methyl-acetamide → 2-{7-[5-Chloro-4-((1R,2R)-2-methanesulfonylamino-cyclohexylamino)-pyrimidin-2-ylamino]-1,2,4,5-tetrahydro-benzo[d]azepin-3-yl}-N-methyl-acetamide
Reaktionsgleichung
[NH2:1][C:2]1[CH:17]=[CH:16][C:5]2[CH2:6][CH2:7][N:8]([CH2:11][C:12]([NH:14][CH3:15])=[O:13])[CH2:9][CH2:10][C:4]=2[CH:3]=1.Cl[C:19]1[N:24]=[C:23]([NH:25][C@@H:26]2[CH2:31][CH2:30][CH2:29][CH2:28][C@H:27]2[NH:32][S:33]([CH3:36])(=[O:35])=[O:34])[C:22]([Cl:37])=[CH:21][N:20]=1>>[Cl:37][C:22]1[C:23]([NH:25][C@@H:26]2[CH2:31][CH2:30][CH2:29][CH2:28][C@H:27]2[NH:32][S:33]([CH3:36])(=[O:35])=[O:34])=[N:24][C:19]([NH:1][C:2]2[CH:17]=[CH:16][C:5]3[CH2:6][CH2:7][N:8]([CH2:11][C:12]([NH:14][CH3:15])=[O:13])[CH2:9][CH2:10][C:4]=3[CH:3]=2)=[N:20][CH:21]=1Komponenten
3
Edukt 2
Produkt 1
Versuchsvorschrift
2-{7-[5-Chloro-4-((1R,2R)-2-methanesulfonylamino-cyclohexylamino)-pyrimidin-2-ylamino]-1,2,4,5-tetrahydro-benzo[d]azepin-3-yl}-N-methyl-acetamide was prepared from 2-(7-amino-1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-N-methyl-acetamide and N-[(1R,2R)-2-(2,5-dichloro-pyrimidin-4-ylamino)-cyclohexyl]-methanesulfonamide in an analogous manner to Example 308c. Product isolated as a pale yellow foam (85 mg, 44%). LCMS (m/e) 536 (M+H); 1H-NMR (CDCl3, 400 MHz) δ 7.94 (s, 1H), 7.40-7.23 (m, 3H), 7.06 (d, 1H, J=8.0 Hz), 6.86 (s, 1H), 5.47-5.35 (m, 2H), 3.93-3.81 (m, 1H), 3.31-3.19 (m, 1H), 3.15 (s, 2H), 2.96-2.86 (m, 4H), 2.90 (d, 3H, J=5.0 Hz), 2.81 (s, 3H), 2.78-2.66 (m, 4H), 2.29-2.16 (m, 2H), 1.90-1.79 (m, 2H), 1.46-1.30 (m, 4H).